What's Happening?
Imbed Biosciences has announced that the Centers for Medicare & Medicaid Services (CMS) assigned a Healthcare Common Procedure Coding System (HCPCS) Level II code, A2040, to its Microlyte PainGuard. This synthetic wound matrix incorporates silver for antimicrobial
activity and lidocaine for localized pain management. The new code, effective April 1, 2026, supports billing clarity and claims reporting, facilitating payer engagement and supporting the product's integration into clinical workflows.
Why It's Important?
The assignment of an HCPCS code is a crucial step for Imbed Biosciences, as it enhances billing clarity and supports the reimbursement process for healthcare providers. This development is expected to improve the adoption of Microlyte PainGuard in clinical settings, offering a non-opioid solution for pain management in wound care. The code assignment also reflects the growing recognition of innovative wound care solutions and their potential to improve patient outcomes.
